🇺🇸 FDA
Pipeline program

HiPSC-RPE cells

JSPH-iPSCs-RPE-001

Phase 2 mab active

Quick answer

HiPSC-RPE cells for AMD - Age-Related Macular Degeneration is a Phase 2 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
AMD - Age-Related Macular Degeneration
Phase
Phase 2
Modality
mab
Status
active

Clinical trials